{"id":1729,"date":"2006-05-01T12:06:00","date_gmt":"2006-05-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/leserbrief-impfrisiko-unter-tnf-alpha-antagonisten"},"modified":"2006-05-01T12:06:00","modified_gmt":"2006-05-01T10:06:00","slug":"leserbrief-impfrisiko-unter-tnf-alpha-antagonisten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/leserbrief-impfrisiko-unter-tnf-alpha-antagonisten","title":{"rendered":"Leserbrief: Impfrisiko unter TNF-alpha-Antagonisten?"},"content":{"rendered":"<p>Frage von Dr. M.H.W. aus Bovenden: >> Erh\u00f6ht sich das Impfrisiko unter gleichzeitiger Behandlung mit TNF-Antagonisten? Klinische Studien zu dieser Frage gibt es nicht. Tumor-Nekrose-Faktor alpha (TNF-\u03b1) z\u00e4hlt zu den Zytokinen, die f\u00fcr die Ausreifung von dendritischen Zellen, den effektivsten Antigen-pr\u00e4sentierenden Zellen (APC), verantwortlich sind. Nach Applikation eines Impfstoffs wird dessen Antigen von den dermalen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frage von Dr. M.H.W. aus Bovenden: >> Erh\u00f6ht sich das Impfrisiko unter gleichzeitiger Behandlung mit TNF-Antagonisten? Klinische Studien zu dieser Frage gibt es nicht. Tumor-Nekrose-Faktor alpha (TNF-\u03b1) z\u00e4hlt zu den Zytokinen, die f\u00fcr die Ausreifung von dendritischen Zellen, den effektivsten Antigen-pr\u00e4sentierenden Zellen (APC), verantwortlich sind. Nach Applikation eines Impfstoffs wird dessen Antigen von den dermalen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2354,2339,1263,1262,1257,1260,1261,1259,1258,1264],"class_list":["post-1729","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-impfungen","tag-schutzimpfungen","tag-tnf-alpha-antagonisten","tag-tnf-alpha-antikoerper","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-antikoerper","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1729"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1729\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}